Comparison of noninvasive models of fibrosis in chronic hepatitis B

  title={Comparison of noninvasive models of fibrosis in chronic hepatitis B},
  author={Spiro C. Raftopoulos and Jacob George and Marc Bourlière and Enrico Rossi and W. Bastiaan de Boer and Gary P. Jeffrey and Max K. Bulsara and David John Speers and Gerry Macquillan and Helena L. Ching and Nickolas Kontorinis and Wendy S C Cheng and James P. Flexman and Soraya Fermoyle and Paul H. Rigby and L L Walsh and Duncan J. Mcleod and Leon A. Adams},
  journal={Hepatology International},
Background and goalsLiver fibrosis influences treatment and surveillance strategies in chronic hepatitis B (CHB). This multicenter study aimed to examine the accuracy of serum fibrosis models in CHB patients including those with low alanine aminotransferase (ALT) levels and serially in those undergoing treatment.MethodWe examined noninvasive fibrosis models [Hepascore, Fibrotest, APRI, hepatitis e antigen (HBeAg)-positive and -negative models] in 179 CHB patients who underwent liver biopsy and… 

Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B

FT substantially reduces need for liver biopsy, especially when used in combination with LS, and provides good fibrosis prediction, with comparable outcomes to LS in Asian chronic hepatitis B patients.

Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B

Transient elastography, FibroTest and API are the mostwidely validated non-invasive method for liverfibrosis assessment and a combined application of tran-sientElastography and biomarkers may be the preferredcourse of action.

Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection

It is demonstrated that ELF has good performance in detection of liver fibrosis in patients with CHB, and when compared, TE performs better in Detection of severe fibrosis/cirrhosis.

Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology

Although HA and Hepascore may be useful where the disease aetiology is known, particularly in established hepatitis C virus, the high cost of false positives and false negatives are such that neither a reliable enough to replace biopsy without substantial further characterization.

High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis

When using non-fasting serum samples, hyaluronic acid and to a lesser extent, the Hepascore model display large within-individual variations in both health and chronic liver disease.

Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis

The meta‐analysis suggests that APRI and FIB‐4 can identify hepatitis B‐related fibrosis with a moderate sensitivity and accuracy.

Transient Elastography is Superior to the FIB 4 Index, Aspartate Platelet Ratio Index, Aspartate Alanine Aminotransferase Ratio, Age Platelet Index and Fibrosis Index in Diagnosing Fibrosis in Chronic Hepatitis B Patients

Transient Elastography has excellent accuracy for F4 and F≥3 and can reduce the need for liver biopsies in the majority of chronic hepatitis B patients and was the most superior non-invasive measure for every stage of fibrosis when compared with FIB-4I, APRI, API, AAR and FI.



Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

The FibroTest score could not accurately predict the presence or absence of significant liver fibrosis in Australian hepatitis C patients.

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients.

Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model

A predictive model with a combination of easily accessible variables identified HBeAg‐positive chronic hepatitis B patients with and without significant fibrosis with a high degree of accuracy and may decrease the need for liver biopsy in staging of 35.5% CHB.

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C

It is shown that a simple index using readily available laboratory results can identify CHC patients with significant fibrosis and cirrhosis with a high degree of accuracy and may decrease the need for staging liver biopsy specimens among patients with CHC.

Noninvasive Markers of Liver Fibrosis and Inflammation in Chronic Hepatitis B-Virus Related Liver Disease

Significant hepatic fibrosis and necroinflammation can reliably be predicted using routinely checked tests and HBV DNA levels.

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

FibroScan is a simple and effective method for assessing liver fibrosis, with similar performance to FibroTest and APRI, and could avoid a biopsy procedure in most patients with chronic hepatitis C.

Histologic Evidence of Active Liver Injury in Chronic Hepatitis B Patients With Normal Range or Minimally Elevated Alanine Aminotransferase Levels

Use of the modified ALT ULN will likely improve accuracy in identifying patients who may have HEALD compared with conventional laboratory ULN.

Fibrosis and disease progression in hepatitis C

Serum markers for fibrosis are not reliable and need to be improved and validated, and liver biopsy provides the most accurate information on the stage of fibrosis and grade of necroinflammation, both of which have prognostic significance.